Results 31 to 40 of about 6,560 (205)

Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis

Antibiotics, 2023
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is unknown. The goal of the current meta-analysis was to compare the real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 during the ...
Chienhsiu Huang, Tsung-Lung Lu, Lichen Lin   +2 more
doaj   +1 more source

Molnupiravir and Its Antiviral Activity Against COVID-19

Frontiers in Immunology, 2022
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat and economic burden.
Lili Tian, Zehan Pang, Maochen Li, Fuxing Lou, Xiaoping An, Shaozhou Zhu, Lihua Song, Yigang Tong, Huahao Fan, Junfen Fan   +9 more
doaj   +1 more source

Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?

Therapeutic Advances in Drug Safety, 2022
Plain Language Summary Could natural plant pigment (chlorophyll) derivatives (chlorophyllins) improve the safety of the antiviral Molnupiravir, used to treat COVID-19 disease?
Nicole F. Clark, Andrew W. Taylor-Robinson, Kirsten Heimann   +2 more
doaj   +1 more source

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

Frontiers in Pharmacology, 2023
Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as the basis for our study, which relies on the Food and Drug Administration Adverse Event Reporting System (FAERS).
Yankun Liang, Yankun Liang, Lin Ma, Yuting Wang, Jingping Zheng, Ling Su, Jun Lyu, Jun Lyu   +7 more
doaj   +1 more source

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context

EClinicalMedicine, 2023
Summary: Background: Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for COVID-19 treatment, but direct comparisons of their effectiveness have been limited.
Eric Yuk Fai Wan, Vincent Ka Chun Yan, Zoey Cho Ting Wong, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Xue Li, Carlos King Ho Wong, Ivan Fan Ngai Hung, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan   +10 more
doaj   +1 more source

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes [PDF]

, 2023
Molnupiravir, an antiviral medication that has been widely used against SARS-CoV-2, acts by inducing mutations in the virus genome during replication.
Alessandra Løchen (9531950), Thomas P Peacock (8155782), Hassan Hartman (592088), Ryan Hisner (17402131), Theo Sanderson (5662720), I’ah Donovan-Banfield (14100447), Christopher Ruis (4182916)   +6 more
core   +4 more sources

Molnupiravir. Chinese

, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 SIMPLIFIED CHINESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core   +1 more source

Earth-friendly-assessed silver-nanoparticles spectrophotometric method for rapid and sensitive analysis of Molnupiravir, an FDA-approved candidate for COVID-19: application on pharmaceutical formulation and dissolution test

BMC Chemistry, 2023
Molnupiravir is the first oral direct-acting antiviral prodrug recently approved for the COVID-19 pandemic. Here and for the first time, we present a novel, sensitive, robust, and simple silver-nanoparticles spectrophotometric technique for molnupiravir ...
Ahmed R. Mohamed, Ebrahim Abolmagd, Israa M. Nour, Mohamed Badrawy, Mohamed A. Hasan   +4 more
doaj   +1 more source

theosanderson/molnupiravir

, 2023
Data and scripts used in "Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases"
Sanderson, Theo, Ruis, Chris
core   +1 more source

Toward a Practical, Two-Step Process for Molnupiravir from Cytidine

, 2021
A two-step synthesis of molnupiravir (1) is presented. This work focuses on the development of practical reaction and purification conditions toward a manufacturing route.
Flavio S. P., Cardoso, Rodger W., Stringham, Natarajan, Vasudevan, Dinesh J., Paymode, Daniel W., Cook, Justina, Burns, Saeed, Ahmad, David, Snead, Appasaheb L., Kadam   +8 more
core   +1 more source